Lilly Asia Ventures has returned for the genomic drug developer's latest round, having already taken part in a $15m pre-series B round just over a year ago.
China-based genomic medicine developer EdiGene has raised approximately $11m in pre-series B2 funding from pharmaceutical firm Eli Lilly and venture capital group IDG Capital.
Eli Lilly provided the capital through Lilly Asia Ventures, the corporate venturing unit that led EdiGene’s $15m pre-series B round in August 2018. The 2018 round included IDG Capital, private equity firm Huagai Capital, VC firm WI Harper Group and unnamed existing shareholders.
Founded in 2015, EdiGene uses genome editing technologies to generate treatments for a wide range of conditions including cancer.
The fresh funding was announced alongside a research collaboration agreement between EdiGene and an unnamed clinical stage biopharmaceutical company that involves the development of T-cell therapies for cancer.
Details of the company’s series A funding have not emerged, though it has said IDG Capital and WI Harper both took part. It is unrelated to EdiGene, the Japan-based genetic disorder treatment developer whose backers include imaging technology producer Fujifilm.
